Recipient-derived vs. donor-derived CAR-T-cell therapy in relapsed B-cell acute lymphoblastic leukemia patients after transplantation: A multi-center retropective study
Both recipient-derived and donor-derived CD19 CAR-T cell therapies are effective treatment options for B-ALL relapsed post-allo-HSCT patients. HID-derived CAR-T cells offer a longer EFS and may be considered the optimal choice.
Authors
- Hai Yi (ORCID: https://orcid.org/0000-0003-3794-266X)
- Shangjun Chen (ORCID: https://orcid.org/0000-0003-3582-4336)
- Ruihao Huang (ORCID: https://orcid.org/0000-0001-5806-4961)
- Sanfang Tu (ORCID: https://orcid.org/0000-0001-8834-6839)
- Xi Zhang (ORCID: https://orcid.org/0000-0003-1340-7128)
- Yongxian Hu (ORCID: https://orcid.org/0000-0001-9564-1852)
- Cheng Zhang (ORCID: https://orcid.org/0000-0003-3843-1562)
- Lichao Liu (ORCID: https://orcid.org/0000-0003-4254-7453)
- Jian Zhou (ORCID: https://orcid.org/0000-0001-8290-3104)
- Yuhua Li
- Qiuying Gao (ORCID: https://orcid.org/0000-0001-9133-1160)
- Xu Tan (ORCID: https://orcid.org/0009-0007-6126-6549)
- Xiaoqi Wang
Institutions
- Army Medical University (CN)
- Shanxi Medical University (CN)
- Shaanxi Provincial People's Hospital (CN)
- Chengdu Military General Hospital (CN)
- Xinqiao Hospital (CN)
- Zhujiang Hospital (CN)
- Henan Cancer Hospital (CN)
- Tongji Hospital (CN)
- Shanxi Provincial People’s Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Huazhong University of Science and Technology (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Chinese Medical Journal
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1097/cm9.0000000000003855
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05